BIO-RAD LABORATORIES, INC.
BIONYSEHealthcare · Laboratory Analytical Instruments · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $2.58B | $2.57B | $2.67B | $2.80B | $2.92B | $2.55B |
| Operating income | $47.2M | $269.0M | $337.8M | $482.6M | $500.3M | $421.3M |
| Net income | $759.9M | −$1.84B | −$637.3M | −$3.63B | $4.25B | $3.81B |
| Total assets | $10.58B | $9.36B | $12.30B | $13.50B | $17.80B | $12.97B |
| Total liabilities | $3.12B | $2.79B | $3.56B | $3.89B | $4.11B | $3.09B |
| Equity | $7.45B | $6.57B | $8.74B | $9.62B | $13.69B | $9.89B |
| EPS (diluted) | $27.85 | $-65.36 | $-21.82 | $-112.50 | $140.83 | $126.47 |
| Shares out. | 27.3M | 28.2M | 29.2M | 29.8M | 30.2M | 30.2M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- 1.8%
- Net margin
- 29.4%
- Return on equity
- 10.2%
- Return on assets
- 7.2%
- Return on capital (ROCE)
- 0.5%
- Liabilities / assets
- 29.5%
- Debt / equity
- 0.42×
- Book value / share
- $273.22
- Revenue growth (YoY)
- 0.7%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- 6.54safe
- Accruals / assets
- 2.2%clean
- Beneish M-Score
- -2.32normal
- Piotroski F-Score
- 5/9mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 severe● 6 good- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Operating margin is positive
- Revenue is growing year-over-year
- Conservative leverage (liabilities < 50% of assets)
- Positive operating cash flow
- Clean earnings (low accruals)
- Altman Z″ in the safe zone
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Kmissed a reporting deadline ↗Mar 4, 2019
- NT 10-Kmissed a reporting deadline ↗Mar 2, 2018
- NT 10-Kmissed a reporting deadline ↗Mar 4, 2014
- NT 10-Kmissed a reporting deadline ↗Mar 4, 2013
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Vanguard Group IncPassive (13G)Mar 26, 2026
- Schwartz Norman DActivist (13D)Oct 30, 2025
- Blackrock, Inc.Passive (13G)Oct 17, 2025
- First Eagle Investment Management, LlcPassive (13G)Aug 6, 2025
- Schwartz Alice NActivist (13D)Jul 18, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Enloe Courtney COfficer — EVP, General Counsel & Sec | Apr 24, 2026 | Option exercise | 186 | $0.00 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 1.3M | 2.9 | +22.8% |
| Apr 30, 2026 | 1.1M | 3.7 | +2.3% |
| Apr 15, 2026 | 1.1M | 4.3 | -12.1% |
| Mar 31, 2026 | 1.2M | 3.4 | +20.5% |
| Mar 13, 2026 | 1.0M | 3.8 | +6.4% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Results of operations · Regulation FD disclosureApr 30, 2026
- Director / officer change · Shareholder voteApr 24, 2026
- Regulation FD disclosureFeb 19, 2026
- Results of operations · Regulation FD disclosureFeb 12, 2026
- Results of operations · Regulation FD disclosureOct 29, 2025
- Regulation FD disclosureSep 30, 2025
- Regulation FD disclosureAug 26, 2025
- Results of operations · Regulation FD disclosureJul 31, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.